MetaCap

ABVC BioPharma (ABVC) vs Lite Strategy (LITS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lite Strategy (LITS) has outperformed ABVC BioPharma (ABVC) over the past year, losing 52.8% versus a loss of 67.8%. Over five years, ABVC leads with a -97.3% price change compared with -98.5% for LITS. Lite Strategy is the larger company by market cap ($24.0 million vs $23.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABVC-67.80%LITS-52.79%
+17%-30%-78%
Nov 21, 20251 yearNov 20, 2026
ABVC-97.37%LITS-98.56%
+20%-42%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABVC versus LITS key metrics
MetricABVCLITS
Share price$0.8663$0.8026
Market cap$23.37M$23.99M
1-day change-1.56%-4.03%
YTD return-59.33%-39.20%
1-year return-67.80%-52.79%
5-year return-97.29%-98.46%
EPS (TTM)$-0.20$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$296.00K—
Revenue growth (YoY)-41.91%—
Net income (latest FY)$-7.91M$-71.15M
Operating margin-2415.97%—
Net margin-2671.81%—
52-week high$2.87$1.99
52-week low$0.707$0.69
Distance from 52-week high-69.82%-59.67%
Average volume81.92K524.33K
Shares outstanding26.98M29.88M
Employees165
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LITS has outperformed ABVC by 15.0 percentage points over the past year.

About ABVC BioPharma

ABVC stock →

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

About Lite Strategy

LITS stock →

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

ABVC vs LITS FAQ

Which is bigger, ABVC BioPharma or Lite Strategy?

Lite Strategy (LITS) is larger, with a market capitalization of $23.99M compared with $23.37M for ABVC BioPharma (ABVC).

Which stock has performed better over the past year, ABVC or LITS?

LITS returned -52.79% over the past 12 months, compared with -67.80% for ABVC (price return, excluding dividends). Past performance does not predict future results.

Are ABVC BioPharma and Lite Strategy in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons